632P - KRAS mutation and protein levels in gastric cancer patients and response to MEK inhibitors

Date 08 October 2016
Event ESMO 2016 Congress
Session Poster Display
Topics Gastric Cancer
Presenter Jia Wei
Citation Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371
Authors J. Wei, Y.-. Huang, N. Wu, L. Yu, B. Liu
  • Medical Oncology, The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, 210008 - Nanjing/CN



Recent studies have suggested that KRAS plays an important role in gastric cancer. The aim of this study was to assess the prognostic effect of KRAS mutation and expression levels in gastric cancer patients and to explore its potential role in targeted therapy.


We examined KRAS protein levels in 132 stage I-IV gastric cancer using immunochemistry. KRAS mutation was detected by next generation exome sequencing. KRAS mutation was examined in five human gastric cell lines (AGS, SNU601, SNU668, KATO-III and NUGC-4) by Sanger sequencing. Cytosensitivity of MEK inhibitors (AZD6244) in the five cell lines was examined by MTT.


The median age of the total number of 132 gastric cancer patients was 58 years (range: 30-82). There were 75 gastric cancer samples with the pathology of signet-ring cell carcinoma (SRCC), while another 57 samples with adenocarcinoma. 80% of gastric SRCC samples have high expression of KRAS protein compared with 34.69% of gastric adenocarcinomas (P 


KRAS is highly expressed in SRCC. Patients with KRAS mutations have shorter OS. Gastric SRCC cell lines with KRAS mutation are sensitive to MEK inhibitor (AZD6244). The results provide insights into the important role of mutant KRAS in the prognosis and response to MEK inhibitor of gastric SRCC patients.

Clinical trial identification


Legal entity responsible for the study

Jia Wei


Nation Science Foundation


All authors have declared no conflicts of interest.